|
1 March 2002. Elan Corporation and American Home Products announced today what
everyone already expected: Their phase 2a clinical trial of a vaccine made of
synthetic Aβ1-42 has ended prematurely because 15
volunteers developed cerebral inflammation. See stories
below on dosing suspension last month.
The company press release states that most of the 15 patients have improved
thanks to antiinflammatory treatment, but did not say how many have not responded
and how ill they are. The roughly 360 volunteers who have been vaccinated will,
of course, be followed further. To date, the company has not publicly explained
the nature of the inflammation. See upcoming chat on AD immunotherapy.-Gabrielle
Strobel.
See
full text press release.
|
Home
